Table 2.
ostoperative Follow up characteristics of 667 patients with laser enucleation of the prostate from the University Hospital Frankfurt between 11/2017 and 01/2022, stratified according to surgeon’s caseload
| N | Overall, N = 677a | Caseload < 25, N = 84 (12%)a | Caseload 25–49, N = 75 (11%)a | Caseload 50–99, N = 82 (12%)a | Caseload 100–199, N = 106 (16%)a | Caseload > = 200, N = 330 (49%)a | p valueb | |
|---|---|---|---|---|---|---|---|---|
| Δ IPSS | 224 | 11 (5, 17) | 8 (3, 14) | 13 (3, 17) | 14 (6, 18) | 14 (8, 16) | 11 (6, 17) | 0.6 |
| Δ Qol | 377 | 3.0 (4.0, 1.0) | 2.0 (4.0, 1.0) | 2.0 (4.0, 0.0) | 3.0 (4.0, 1.0) | 3.0 (4.0, 2.0) | 3.0 (4.0, 1.0) | 0.3 |
| Δ ICIQ | 341 | 0.0 (-2.0, 4.0) | 0.0 (-2.5, 5.0) | 0.0 (-0.5, 4.5) | 0.0 (-5.8, 3.8) | 0.0 (0.0, 2.0) | 0.0 (-2.0, 4.0) | 0.9 |
| Δ pads | 160 | 0.0 (0.0, 1.0) | 0.0 (-0.75, 1.0) | 0.0 (0.0, 1.0) | 0.0 (0.0,1.0) | 0.0 (-1.50, 0.0) | 0.0 (0.0, 1.0) | 0.2 |
| Δ Qmax | 257 | 9 (3, 16) | 10 (4, 15) | 12 (3, 20) | 9 (5, 14) | 10 (2, 16) | 8 (4, 14) | 0.8 |
| Δ Post void residual urine | 344 | 60 (15,150) | 56 (1, 128) | 100 (42, 226) | 80 (18, 150) | 72 (14, 200) | 50 (15, 138) | 0.5 |
| 30 day-complications | 667 | 0.2 | ||||||
| None | 486 (72%) | 58 (69%) | 49 (65%) | 56 (68%) | 78 (74%) | 245 (74%) | ||
| Minor (Clavien Dindo ≤ 3a) | 142 (21%) | 19 (23%) | 24 (32%) | 17 (21%) | 22 (21%) | 60 (18%) | ||
| Major (Clavien Dindo ≥ 3b) | 49 (7.2%) | 7 (8.3%) | 2 (2.7%) | 9 (11%) | 6 (5.7%) | 25 (7.6%) | ||
| Post OP transurethral catheter | 664 | 25 (3.8%) | 5 (6.1%) | 2 (2.7%) | 4 (4.9%) | 5 (4.7%) | 9 (2.8%) | 0.5 |
| Continencec | 464 | 0.2 | ||||||
| Post OP continent | 443 (95%) | 48 (91%) | 50 (94%) | 42 (91%) | 72 (97%) | 231 (97%) | ||
| De novo incontinent | 18 (3.9%) | 4 (7.5%) | 2 (3.8%) | 4 (8.7%) | 2 (2.7%) | 6 (2.5%) | ||
| Preoperatively incontinent | 3 (0.6%) | 1 (1.9%) | 1 (1.9%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
IPSS International Prostate Symptoms Score; Qol quality of life; ICIQ International Consultation on Incontinence Questionnaire; Qmax, peak urine flow
aMedian (Interquartile range IQR); n (%)
bKruskal–Wallis rank sum test; Pearson's Chi-square test; Fisher's exact test
cDefined as usage of 0–1 pads per day